Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$243.00K$243.00Kderived+62.0% vs Q4 2024 Net Income-$7.22M-$7.22MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$7,827,000N/M Operating Cash Flowderived-$5,967,000N/M Free Cash Flowderived-$5,967,000N/M Margins · derivedOperating margin-3221.0%+5160.3 pt vs Q4 2024
Net margin-2969.5%+4888.5 pt vs Q4 2024
ended Dec 31, 2025 · filed Feb 24, 2026 · 55 d after period end